Oncolytics Biotech (ONC) Competitors C$1.19 -0.12 (-9.16%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades ONC vs. PLI, ABCN, EMC, FRX, BCT, IPA, MDNA, SCYB, COM, and THShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Medicenna Therapeutics (MDNA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Theratechnologies (TH). These companies are all part of the "biotechnology" industry. Oncolytics Biotech vs. ProMetic Life Sciences VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Medicenna Therapeutics Scythian Biosciences 138267 (COM.TO) Theratechnologies Oncolytics Biotech (TSE:ONC) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking. Do institutionals & insiders hold more shares of ONC or PLI? 1.8% of Oncolytics Biotech shares are held by institutional investors. 3.8% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ONC or PLI more profitable? ProMetic Life Sciences' return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -138.22% -71.33% ProMetic Life Sciences N/A N/A N/A Do analysts rate ONC or PLI? Oncolytics Biotech presently has a consensus price target of C$3.50, indicating a potential upside of 194.12%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than ProMetic Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProMetic Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in ONC or PLI? ProMetic Life Sciences received 246 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 74.81% of users gave Oncolytics Biotech an outperform vote while only 67.69% of users gave ProMetic Life Sciences an outperform vote. CompanyUnderperformOutperformOncolytics BiotechOutperform Votes19674.81% Underperform Votes6625.19% ProMetic Life SciencesOutperform Votes44267.69% Underperform Votes21132.31% Which has preferable earnings and valuation, ONC or PLI? Oncolytics Biotech has higher earnings, but lower revenue than ProMetic Life Sciences. Oncolytics Biotech is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-C$28.02M-C$0.38-3.13ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A Does the media prefer ONC or PLI? In the previous week, Oncolytics Biotech had 4 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 4 mentions for Oncolytics Biotech and 0 mentions for ProMetic Life Sciences. ProMetic Life Sciences' average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.48 indicating that ProMetic Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Oncolytics Biotech Neutral ProMetic Life Sciences Neutral SummaryOncolytics Biotech beats ProMetic Life Sciences on 9 of the 15 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricOncolytics BiotechBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$91.46MC$164.65MC$5.14BC$6.07BDividend Yield0.31%3.64%5.09%5.42%P/E Ratio-3.13115.5190.0526.16Price / SalesN/A18,239.951,117.141,332.85Price / Cash4.2212.7543.0482.30Price / Book4.968.504.783.07Net Income-C$28.02M-C$20.67MC$120.31MC$295.24M7 Day Performance0.85%-1.04%-1.92%-2.48%1 Month Performance-13.14%136.65%11.51%-0.78%1 Year Performance-29.59%137.57%30.61%34.67% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncolytics Biotech1.0543 of 5 starsC$1.19-9.2%C$3.50+194.1%-29.6%C$91.46MN/A-3.1329News CoverageHigh Trading VolumePLIProMetic Life SciencesN/AC$13.60+0.2%N/AN/AC$317.06MC$39.91M-0.22487ABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$8.51-2.0%N/A-37.9%C$232.83MC$48.89M85.1010Analyst RevisionNews CoverageBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080News CoverageGap DownMDNAMedicenna TherapeuticsN/AC$1.72-2.8%N/A+317.1%C$131.46MN/A-4.6620SCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AC$2.95-2.6%N/AN/AC$102.19MN/A0.00N/ATHTheratechnologiesN/AC$2.21+2.8%N/A+23.8%C$101.62MC$82.57M-11.94103News CoverageHigh Trading Volume Related Companies and Tools Related Companies ProMetic Life Sciences Alternatives VIVO Cannabis Alternatives Emblem Alternatives Fennec Pharmaceuticals Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Medicenna Therapeutics Alternatives Scythian Biosciences Alternatives 138267 (COM.TO) Alternatives Theratechnologies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:ONC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
